- Home
- HEQ vs UNCY Comparison
HEQ vs UNCY Comparison
Compare HEQ & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HEQ | UNCY |
|---|---|---|
| Founded | N/A | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 130.0M | 145.3M |
| IPO Year | 2010 | 2021 |
Fundamental Metrics
Financial Performance| Metric | HEQ | UNCY |
|---|---|---|
| Price | $10.99 | $6.63 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $38.00 |
| AVG Volume (30 Days) | 44.9K | ★ 489.9K |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $675,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $407.73 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.73 | $0.47 |
| 52 Week High | $11.58 | $7.57 |
Technical Indicators
Market Signals| Indicator | HEQ | UNCY |
|---|---|---|
| Relative Strength Index (RSI) | 51.75 | 49.09 |
| Support Level | $10.53 | $6.48 |
| Resistance Level | $11.13 | $7.12 |
| Average True Range (ATR) | 0.22 | 0.42 |
| MACD | 0.05 | -0.01 |
| Stochastic Oscillator | 72.73 | 41.22 |
Price Performance
Historical ComparisonAbout HEQ John Hancock Hedged Equity & Income Fund of Beneficial Interest
John Hancock Hedged Equity & Income Fund is a closed-end management investment company. Its investment objective is to provide total return, with a focus on current income and gains, and to include long-term capital appreciation. It invests in various sectors such as financials, consumer discretionary, information technology, energy, healthcare, materials, real estate, consumer staples, short-term investments, and others.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.